Burning Rock Biotech Limited BNR

BNR Company Overview

Burning Rock Biotech Limited is a molecular diagnostics company focused on precision oncology, operating primarily in the biotechnology and clinical diagnostics industries. The company develops and commercializes next-generation sequencing (NGS)-based cancer diagnostics that support clinical decision-making, therapy selection, and drug development. Its offerings are used by hospitals, physicians, and pharmaceutical companies to guide targeted cancer treatments and research programs.

The company generates revenue mainly through oncology testing services, in-hospital diagnostic solutions, and pharmaceutical research services. Burning Rock is positioned as a leading independent precision oncology testing provider in China, with strategic advantages in proprietary NGS panels, bioinformatics capabilities, and extensive clinical data assets. Founded in 2014, the company expanded rapidly alongside the adoption of precision medicine in China and completed an initial public offering on the NASDAQ in 2020 under the ticker BNR.